Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2137644 | Leukemia Research | 2011 | 4 Pages |
Abstract
There is no standard salvage regimen for AML. We retrospectively compared two commonly used regimens at our institution: CLAG and MEC. The complete response rate (CR) was 37.9% for CLAG (n = 97) and 23.8% for MEC (n = 65) (P = 0.048), with median overall survival (OS) of 7.3 and 4.5 months, respectively (P = 0.05). In primary refractory disease, CR was 45.5% for CLAG and 22.2% for MEC (P = 0.09), with median OS of 11 and 4.5 months, respectively (P = 0.07). In first relapse, CR was 36.8% and 25.9% (P = 0.35) and median OS was 6.7 and 6.7 months, respectively (P = 0.87). Our data support use of CLAG for RR-AML.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Samantha L. Price, Jeffrey E. Lancet, Timothy J. George, Gene A. Wetzstein, Alan F. List, Viet Q. Ho, Hugo F. Fernandez, Javier Pinilla-Ibarz, Mohamed A. Kharfan-Dabaja, Rami S. Komrokji,